Re:Otonomo, with nearly $55M in funding, is cloning our product
by sgustard on Monday April 22, 2019 @04:21PM
(#19722542)
VCs love to tout how they reject 99.9% of their pitches. What's the competitive advantage for them to fund an investment with minimal technical review? Wouldn't avoiding the next Theranos be worth it?
[ Parent
| on HN ]
Re:Otonomo, with nearly $55M in funding, is cloning our product
by manigandham on Monday April 22, 2019 @04:24PM
(#19722585)
No. VC is about numbers, getting into as many deals as possible because a very small number return enough to pay for the fund. 99% of deals are expected to fail. In-depth due diligence costs too and would take away money that could be better spent on just another deal.